BR112012016330B8 - ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos - Google Patents

ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos

Info

Publication number
BR112012016330B8
BR112012016330B8 BR112012016330A BR112012016330A BR112012016330B8 BR 112012016330 B8 BR112012016330 B8 BR 112012016330B8 BR 112012016330 A BR112012016330 A BR 112012016330A BR 112012016330 A BR112012016330 A BR 112012016330A BR 112012016330 B8 BR112012016330 B8 BR 112012016330B8
Authority
BR
Brazil
Prior art keywords
ampk
activators
pyridinedione
thieno
same
Prior art date
Application number
BR112012016330A
Other languages
English (en)
Other versions
BR112012016330B1 (pt
BR112012016330A2 (pt
Inventor
Charon Christine
Cravo Daniel
Lepifre Franck
Durand Jean-Denis
Faveriel Laurent
Hallakou-Bozec Sophie
Bolze Sébastien
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of BR112012016330A2 publication Critical patent/BR112012016330A2/pt
Publication of BR112012016330B1 publication Critical patent/BR112012016330B1/pt
Publication of BR112012016330B8 publication Critical patent/BR112012016330B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

ativadores de tieno [2, 3-b] piridinadiona de ampk e usos terapêuticos dos mesmos. a invenção refere-se a compostos que são ativadores diretos de ampk (proteína cinase ativada por amp) e seu uso no tratamento de distúrbios regulados por ativação de ampk. por exemplo, compostos de acordo com a invenção são úteis para o tratamento de diabetes, síndrome metabólica, obesidade, inflamação, câncer e doenças cardiovasculares.
BR112012016330A 2009-12-29 2010-12-28 ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos BR112012016330B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306344,4 2009-12-29
EP09306344 2009-12-29
PCT/EP2010/070811 WO2011080277A1 (en) 2009-12-29 2010-12-28 Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
BR112012016330A2 BR112012016330A2 (pt) 2018-04-03
BR112012016330B1 BR112012016330B1 (pt) 2021-03-23
BR112012016330B8 true BR112012016330B8 (pt) 2021-05-25

Family

ID=41691577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016330A BR112012016330B8 (pt) 2009-12-29 2010-12-28 ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos

Country Status (24)

Country Link
US (1) US9365584B2 (pt)
EP (1) EP2519527B1 (pt)
JP (1) JP5559894B2 (pt)
KR (1) KR101469002B1 (pt)
CN (1) CN102803269B (pt)
AU (1) AU2010338280B2 (pt)
BR (1) BR112012016330B8 (pt)
CA (1) CA2784553C (pt)
CY (1) CY1114952T1 (pt)
DK (1) DK2519527T3 (pt)
EA (1) EA020588B1 (pt)
ES (1) ES2445537T3 (pt)
HR (1) HRP20140035T1 (pt)
IL (1) IL220432A (pt)
ME (1) ME01558B (pt)
MX (1) MX2012007548A (pt)
PL (1) PL2519527T3 (pt)
PT (1) PT2519527E (pt)
RS (1) RS53282B (pt)
SI (1) SI2519527T1 (pt)
SM (1) SMT201400013B (pt)
TW (1) TWI574968B (pt)
WO (1) WO2011080277A1 (pt)
ZA (1) ZA201205604B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104105485B (zh) * 2011-11-11 2017-04-12 吉利德阿波罗公司 Acc抑制剂和其用途
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
WO2017011917A1 (en) * 2015-07-23 2017-01-26 Thrasos Therapeutics Inc. Methods for treating and preventing polycystic kidney diseases (pkd) using amp-activated protein kinase (ampk) modulators and activators
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
ES2855348T3 (es) 2015-11-25 2021-09-23 Gilead Apollo Llc Inhibidores de éster ACC y usos de los mismos
SI3380480T1 (sl) 2015-11-25 2023-04-28 Gilead Apollo, Llc Pirazolni inhibitorji ACC in uporabe le-teh
EP3379933B1 (en) 2015-11-25 2023-02-15 Gilead Apollo, LLC Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
CN108349994B (zh) 2015-11-25 2021-06-22 吉利德阿波罗公司 三唑acc抑制剂及其用途
CA3220447A1 (en) 2016-03-02 2017-09-08 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
US10793527B2 (en) 2016-09-07 2020-10-06 National Yang-Ming University Adenosine monophosphate-activated protein kinase agonist
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
WO2019185413A1 (en) 2018-03-27 2019-10-03 Basf Se Pesticidal substituted cyclopropyl derivatives
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2009124636A1 (en) * 2008-04-11 2009-10-15 Merck Patent Gmbh Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Also Published As

Publication number Publication date
ZA201205604B (en) 2013-05-29
WO2011080277A1 (en) 2011-07-07
US20130053401A1 (en) 2013-02-28
EA201200975A1 (ru) 2012-12-28
EP2519527A1 (en) 2012-11-07
EA020588B1 (ru) 2014-12-30
DK2519527T3 (da) 2014-01-27
SMT201400013B (it) 2014-05-07
KR20120120232A (ko) 2012-11-01
PL2519527T3 (pl) 2014-06-30
HRP20140035T1 (hr) 2014-02-14
ME01558B (me) 2014-04-20
CN102803269B (zh) 2016-01-13
JP2013515758A (ja) 2013-05-09
JP5559894B2 (ja) 2014-07-23
MX2012007548A (es) 2012-07-23
IL220432A (en) 2015-02-26
BR112012016330B1 (pt) 2021-03-23
CA2784553A1 (en) 2011-07-07
CN102803269A (zh) 2012-11-28
AU2010338280A1 (en) 2012-07-26
RS53282B (en) 2014-08-29
SI2519527T1 (sl) 2014-06-30
PT2519527E (pt) 2014-02-17
TWI574968B (zh) 2017-03-21
EP2519527B1 (en) 2013-12-18
AU2010338280B2 (en) 2013-08-22
TW201144318A (en) 2011-12-16
CY1114952T1 (el) 2016-12-14
KR101469002B1 (ko) 2014-12-04
ES2445537T3 (es) 2014-03-03
BR112012016330A2 (pt) 2018-04-03
CA2784553C (en) 2014-08-19
US9365584B2 (en) 2016-06-14

Similar Documents

Publication Publication Date Title
BR112012016330B8 (pt) ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
BRPI0817503B8 (pt) derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
CL2007001166A1 (es) Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
BRPI0615145A2 (pt) derivados de xantina como agonistas hm74a seletivos
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CL2007001167A1 (es) Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica.
BRPI0923231B1 (pt) anticorpo anti-cmet, composição que compreende, e usos do anticorpo e da composição.
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2013003227A1 (es) “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
CL2008003473A1 (es) Compuestos derivados de fenilpiperidina sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso en el tratamiento del trastorno cardiovasculares, tromboembolicos y tumorales; usos in vitro.
CL2008001215A1 (es) Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
UY31922A (es) Compuestos
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
CL2008002185A1 (es) Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.